Evidence map›Paper›PMID 26208151›Full record

ArticlePloS one2015

Vpx-Independent Lentiviral Transduction and shRNA-Mediated Protein Knock-Down in Monocyte-Derived Dendritic Cells.

Wojciech Witkowski, Jolien Vermeire, Alessia Landi, Evelien Naessens, Hanne Vanderstraeten, Hans Nauwynck, Herman Favoreel, Bruno Verhasselt

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wojciech WitkowskiDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, Gent, Belgium.
Jolien VermeireDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, Gent, Belgium.
Alessia LandiDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, Gent, Belgium.
Evelien NaessensDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, Gent, Belgium.
Hanne VanderstraetenDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, Gent, Belgium.
Hans NauwynckVirology lab, Department of Virology, Parasitology and Immunology, Ghent University, Salisburylaan 133 D1, Merelbeke, Belgium.
Herman FavoreelImmunology lab, Department of Virology, Parasitology and Immunology, Ghent University, Salisburylaan 133 D1, Merelbeke, Belgium.
Bruno VerhasseltDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, Gent, Belgium.
Ghent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The function of dendritic cells (DCs) in the immune system is based on their ability to sense and present foreign antigens. Powerful tools to research DC function and to apply in cell-based immunotherapy are either silencing or overexpression of genes achieved by lentiviral transduction. To date, efficient lentiviral transduction of DCs or their monocyte derived counterparts (MDDCs) required high multiplicity of infection (MOI) or the exposure to the HIV-2/SIV protein Vpx to degrade viral restriction factor SAM domain and HD domain-containing protein 1 (SAMHD1). Here we present a Vpx-independent method for efficient (>95%) transduction of MDDCs at lower MOI. The protocol can be used both for ectopic gene expression and knock-down. Introducing shRNA targeting viral entry receptor CD4 and restriction factor SAMHD1 into MDDCs resulted in down-regulation of targeted proteins and, consequently, expected impact on HIV infection. This protocol for MDDCs transduction is robust and free of the potential risk arising from the use of Vpx which creates a virus infection-prone environment, potentially dangerous in clinical setting.

Indexed as

Gene Knockdown TechniquesTransduction, GeneticDendritic CellsGenes, ReporterGenetic VectorsHIV-1HumansLentivirusRNA, Small InterferingViral Regulatory and Accessory ProteinsVirus ReplicationRNA, Small InterferingViral Regulatory and Accessory ProteinsVPX protein, Simian immunodeficiency virus

Identifiers

PMID26208151
PMCPMC4514788
OpenAlexW1526218881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.